AZ'6421
Modify Date: 2025-10-01 20:08:07
AZ'6421 structure
|
Common Name | AZ'6421 | ||
|---|---|---|---|---|
| CAS Number | 2361115-35-5 | Molecular Weight | 975.17 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C52H65F3N6O7S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AZ'6421AZ'6421 acts as Protcolysis Targeting Chimera (PROTAC) to selectively degrade estrogen receptor alpha. AZ'6421 has a potent anti-tumour effect to inhibit the uncontrolled cellular proliferation which arises from malignant disease. AZ'6421 can be used for the research of cancer such as breast cancer[1]. |
| Name | AZ'6421 |
|---|
| Description | AZ'6421 acts as Protcolysis Targeting Chimera (PROTAC) to selectively degrade estrogen receptor alpha. AZ'6421 has a potent anti-tumour effect to inhibit the uncontrolled cellular proliferation which arises from malignant disease. AZ'6421 can be used for the research of cancer such as breast cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.6 nM (ER binding); 0.4 nM (ER degradation)[1] |
| In Vitro | AZ'6421 (example 72) exhibits anti-tumour activity via the ability to degrade the estrogen receptor in a number of different breast cancer cell-lines (MCF-7, CAMA-I, and BT474)[1]. AZ'6421 (0.3 μM) has ER binding and ER degradation with IC50 values of 0.6 nM and 0.4 nM, respectively in MCF-7 cell lines[1]. |
| References |
[1]. Bin Yang, et al. Compounds and their use in treating cancer. Patent WO2019123367A1. |
| Molecular Formula | C52H65F3N6O7S |
|---|---|
| Molecular Weight | 975.17 |